Maintenance therapy for cryptococcosis in patients with AIDS after successful primary therapy: Oral fluconazole (300 mg daily) versus oral itraconazole (300 mg daily)

Clinical Microbiology and Infection

Volumn 5, Issue 9, 1999, Pages 567-570

  De Lalla, Fausto ^a   Pellizzer, Giampietro ^a   Manfrin, Vinicio ^a   Benedetti, Paolo ^a   Franzetti, Marzia ^a   Nicolin, Roberto ^a   Vaglia, Alberto ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

AIDS; Cryptococcosis; Fluconazole; Itraconazole; Maintenance therapy

Indexed keywords

DIDANOSINE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE PANCREATITIS; ADULT; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL;

EID: 0032837680     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00436.x     Document Type: Article

References (14)

1. Dismukes WE. Management of cryptococcosis. Clin Infect Dis 1993, 17(suppl 2): S507-12.
2. Clumeck N, Carael N, Van de Perre P. The African AIDS experience in contrast with the rest of the world. In Leoung G, Mills J, eds. Opportunistic infections in patients with the acquired immunodeficiency syndrome. New York: Marcel Dekker, 1989: 43-56.
3. Clark RA, Greer D, Atkinson W, Valainis GT, Hyslop N. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990; 12: 768-77.
4. Zuger A, Louie E, Holzman RS, Simberkiff MS, Rahal JJ. Cryptococcal disease in patients with acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med 1986; 104: 234-40.
5. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 580-4.
6. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 793-8.
7. Saag MS, Cloud GC, Graybill JR, et al. Comparison of fluconazole versus itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis [abstract 1218]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Washington DC: American Society for Microbiology, 1995: 244.
8. USPHS/IDSA Prevention of opportunistic infections working group. 1997 UPSHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1997; 25(suppl 3): S313-35.
9. Mitchell TG and Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-48
10. de Lalla F, Pellizzer GP, Vaglia A, et al. Amphotericin B as primary therapy for Cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis 1995; 20: 263-6.
11. Van Der Horst C, Saag MS, Cloud GC, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15-21.
12. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992; 14(suppl 1): S161-9.
13. Smith D, van de Velde V, Woestenborghs R, Gazzard BG. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992; 44: 618-19.
14. Venkateswarlu K, Taylor M, Manning NJ, Rinaldi MG, Kelly SL. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41: 748-51.